Replies to post #57130 on Ariad Pharmaceuticals Inc fka ARIA

[lax20m]

Here is data from biotech value board supporting the assertion.


Quote:
22% of CP-CML patients experienced an arterial thrombotic serious adverse event (SAE), and 27 percent of CP-CML patients experienced any arterial thrombotic event


Iclusig arterial thrombotic SAE rate continues to rise even after significant dose reduction. Compare the above numbers from 38-month follow-up against ASCO2014 30-month follow-up of 16% arterial thrombotic SAE, and 23% any arterial thrombotic event.